Comparative Pharmacology
Head-to-head clinical analysis: FLEXERIL versus NORGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXERIL versus NORGESIC.
FLEXERIL vs NORGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant